Pulling SEC filings + quote and writing the call…

MFA FINANCIAL, INC.
Next earnings Aug 4, 2026 (before open) · consensus $0.31 EPS, $60.6M rev
Last earnings -6.0% on 2026-05-05
Cheap mortgage REIT with improving earnings and a fat dividend, but 6.1x leverage and rate sensitivity cap the upside.
Diluted EPS $1.30 · FY2025
Middling fundamentals offset by an attractive price (~421% below fair value) — worth a look on the value angle.
MFA is a levered mortgage REIT whose FY2025 results show genuine operating improvement: net income rose 48% to $177M, diluted EPS jumped to $1.30 (from $0.82), and net interest income grew 14% to $231.1M as the company shifted more capital into Agency MBS (Securities interest income up $60.1M YoY). The MD&A attributes the gain to higher Agency MBS balances plus $15.4M of operating cost cuts, and Other Income benefited from a $87.7M swing in net gains on whole loans measured at fair value. At $9.64 the stock trades at a 7.4x P/E and roughly book value (equity $1.83B / 102M shares ≈ $17.93/share — though that includes preferred), and the $148M dividend on a ~$985M market cap implies a high-single to low-double-digit yield, which is the core attraction.
The filing language tempers the enthusiasm. The asset table shows total debt/net-equity of roughly 6.0–7.8x on the loan books and 8.0x on Agency MBS, with the Legacy RPL/NPL bucket at 10.9x — this is a highly leveraged balance sheet (liabilities/equity 6.14x) where small spread or credit moves matter a lot. MD&A explicitly notes the net interest spread compressed from 2.10% to 1.84% and margin from 2.91% to 2.55% YoY, meaning the earnings growth came from volume and one-off gains, not better unit economics. Derivative results swung by $114M against the company ($78.5M gain in 2024 to $35.5M loss in 2025), and operating cash flow collapsed 62% to $76.2M while cash on hand fell 37% to $213M — a thin liquidity cushion against $11.2B of liabilities. Retained earnings remain deeply negative at -$1.90B, reflecting years of paying out more than earned.
Is MFA a buy? The one-page verdict, explained →
HOLD means own it, don't chase it — harvesting premium against the position matches the verdict.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | $329M | -$232M | $80.2M | $119M | $177M |
| Diluted EPS | $2.63 | -$2.57 | $0.46 | $0.82 | $1.30 |
| Net margin | — | — | — | — | — |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Annual meeting vote results disclosed; routine director/auditor ratifications.
Q1 2026 10-Q filed; ongoing Agency MBS build-up and Non-QM loan portfolio detail.
Q1 2026 10-Q filed; ongoing Agency MBS build-up and Non-QM loan portfolio detail.
2026 proxy: director slate, say-on-pay, auditor ratification — routine governance.
FY2025 10-K: NII +14% to $231M, EPS $1.30; leverage 6.1x, equity flat at $1.83B.
Q4/FY2025 results: NI +48% to $177M, diluted EPS $1.30 vs $0.82 prior year.
Q3 2025 10-Q: continued portfolio growth in Agency MBS and Non-QM whole loans.
Q3 2025 10-Q: continued portfolio growth in Agency MBS and Non-QM whole loans.
Item 5.04 blackout notice to directors/officers under benefit-plan trading rules.
Sources: SEC EDGAR (CIK 0001055160, latest 10-Q filed 2026-05-05) · EODHD · Proprietary analysis · as of 6/25/2026, 2:27:16 PM.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 25, 2026, 10:27 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
| 2026-01-15 | JOSEPHS ROBIN Director | Exercise | 3.47K | |
| 2026-01-15 | Goodman Laurie Director | Exercise | 3.47K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
1195 tracked peers · median